[Beta blocking agents in the treatment of algo-neuro-dystrophies. Apropos of 34 cases].

The authors report results of a series of thirty four cases of algo-neuro-dystrophy treated with beta blockers. This treatment produced favorable results in thirty out of the thirty four cases and the mode of action is discussed.

[The cardiovascular manifestations of Paget's disease].

After reviewing the old ideas (peripheral syndrome and cardiac insufficiency at high outputs) and more recent ideas (arterial and intracardiac vascular calcification), the authors report their experiences based on the study of the histories of 150 patients suffering from Paget's disease followed for several years. First they emphasize the frequent latency of cardiac manifestations looked for systematically by means of the electrocardiogram particularly during evolutive stages of the disease. Electrocardiographic disturbances were observed 91 times and included 43 cases of conduction disorders and 48 of repolarization disorders; their distribution was studied as a function of various inherent parameters, of the patient (age and sex) and of the disease (its evolutive character and its degree of diffusion).

[Modification of uricemia coincident with myocardial infarct].

During myocardial infarction, uric acid values follow a very speciale evolutive curve, with 4 successive phases that might explain the occurrence of an episode of gout during an acute attack.

[Coronary insufficiency in patients with gout].

Statistics on the frequency of coronary insufficiency in patients with gout are contradictory. Nevertheless, it is shown that a correlation often exists between attacks of gout and attacks of angina or acute ischaemic episodes. Finally, these anatomo-clinical studies prove the reality of the gouty heart if only because of the discovery of deposits of intracardiac urates.

[Incidence of hyperuricemia and gout in coronary insufficiency from angina pectoris to myocardial infarct].

The authors try, on one hand, to estimate the role of hyperuricaemia and gout as risk factors in coronary diseases and, on the other, to decide whether the factors react in an isolated or associated fashion.